Acknowledgements The authors thank all those involved in the conduct of the trial and the participants of the study
Market presence of already approved products Clinical development stage in the obesity and diabetes fields Technological differentiation such as oral drugs, multi-agonists, and long-acting formulations Approval and commercialization track record in regional markets including China Executive Summary The market for GLP-1 receptor agonists and related drugs targeting GIP, glucagon, and amylin is expanding from diabetes treatment to obesity, cardiovascular disease, chronic kidney disease, heart failure, MASH, and more
Rauwolscine (Alpha-Yohimbine) (2mg) : Shown to stimulate lipolysis , breaking down stubborn fat and increasing thermogenesis, leading to fat breakdown and energy mobilization
Curcuma longa is a seasonal plant rich in curcuminoid phenolic compounds, which possess remarkable anti-inflammatory and anti-oxidative properties that combat inflammatory and oxidative imbalances, thereby mitigating the occurrence of cataract